Today, the U.S. Food and Drug Administration approved relugolix (Orgovyx) for the treatment of adult patients with advanced prostate cancer. This is the first oral hormone therapy approved for this indication.
In a study reported in JAMA Oncology, Jensen et al found that clonal hematopoiesis of indeterminate potential involving DNA repair genes can interfere with prostate cancer plasma cell-free DNA testing used to determine eligibility for PARP inhibitor treatment and produce false-positive results in a sizable proportion of patients.
In an individual patient meta-analysis reported in the Journal of Clinical Oncology, Daniel E. Spratt, MD, and colleagues found that adjuvant androgen-deprivation therapy (ADT) was associated with improved progression free-survival vs neoadjuvant ADT in patients receiving radiotherapy for localized prostate cancer.
In a systematic review and meta-analysis reported in JAMA Network Open, Myint et al found that androgen receptor inhibitor therapy for prostate cancer was associated with an increased risk of both falls and fractures.
Prostate cancer has lagged behind other solid tumors with regard to molecularly targeted therapy and precision medicine, with no targeted therapies approved specifically in prostate cancer, but that has changed with the recent approval in 2020 of a PARP